The evidence supports over-the-counter access to progestin-only pills: A research summary

Publications and ReportsResearch
Written By Leah Scott

HRA Pharma has submitted an application to the FDA for an over-the-counter (OTC) progestin-only birth control pill (POP). If approved, Opill would be the first OTC birth control pill available in the United States. This research summary highlights the safety and efficacy of POPs, experiences with and interest in using them, and the challenges and barriers to accessing birth control pills in the current prescription-only environment.

Last updated: April 1, 2024

Leah Scott
Previous

Letter from Free the Pill coalition to FDA Commissioner Dr. Robert M. Califf
Next

A commentary on progestin-only pills (POPs) and the “three-hour window” guidelines: Timing of ingestion and mechanisms of action